The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

被引：0
|
作者：
Stadler, W. M.
Figlin, R. A.
Ernstoff, M. S.
Curti, B.
Pendergrass, K.
Srinivas, S.
Canfield, V.
Weissman, C.
Poulin-Costello, M.
Bukowski, R. M.
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] City Hope Comprehens Canc Ctr, Los Angeles, CA USA
[3] Dartmouth Med Sch, Lebanon, NH USA
[4] Providence Portland Med Ctr, Portland, OR USA
[5] Kansas City Canc Ctr, Overland Pk, KS USA
[6] Stanford Univ Hosp, Stanford, CA 94305 USA
[7] Canc Care Associates, Oklahoma City, OK USA
[8] New York Oncol Hematol, Latham, NY USA
[9] Bayer HealthCare, West Haven, CT USA
[10] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5036
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy
    Knox, J. J.
    Figlin, R. A.
    Stadler, W. M.
    McDermott, D. F.
    Gabrail, N.
    Miller, W. H., Jr.
    Hainsworth, J.
    Ryan, C. W.
    Cupit, L.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment
    Drabkin, H. A.
    Figlin, R. A.
    Stadler, W. M.
    Hutson, T. E.
    Hajdenberg, J.
    Chu, L.
    Trent, D.
    Campos, L. T.
    Kelly, F.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: Results from expanded access studies
    Strumberg, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) : 3469 - 3471
  • [4] Safety analysis of the advanced renal cell carcinoma sorafenib (ARCCS) study, an expanded access program
    Bukowski, R.
    Figlin, R.
    Stadler, W.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [5] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM)
    Henderson, C. A.
    Bukowski, R. M.
    Stadler, W. M.
    Dutcher, J. P.
    Kindwall-Keller, T.
    Hotte, S. J.
    Logie, K.
    Baltz, B.
    Wilson, K.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma
    Shi, Hong-Zhe
    Tian, Jun
    Li, Chang-Ling
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (04) : 328 - 333
  • [7] Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: Results from expanded access studies - In reply
    Choueiri, Toni K.
    Bukowski, Ronald M.
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) : 3471 - 3471
  • [8] EFFICACY AND SAFETY OF SUNITINIB IN PATIENTS WITH NON-CLEAR CELL RENAL CELL CARCINOMA
    Lee, J. -L.
    Ahn, J. -H.
    Park, S. H.
    Lim, H. Y.
    Lee, S. H.
    Kim, T. -M.
    Cho, Y. -M.
    Song, C.
    Hong, J. H.
    Kim, C. -S.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 141 - 141
  • [9] Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study
    Plimack, E. R.
    Jonasch, E.
    Bekele, B. N.
    Smith, L. A.
    Araujo, J. C.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)
    Ryan, C. W.
    Bukowski, R. M.
    Figlin, R. A.
    Knox, J. J.
    Hutson, T. E.
    Dutcher, J. P.
    George, J.
    Kirshner, J.
    Humphrey, J.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345